This 1993 retrieval study analyzed interface membrane tissue from 10 failed cemented polyethylene acetabular components. Using in situ hybridization and immunohistochemistry together — for the first time in human arthroplasty tissue — it identified which cytokines are produced in vivo and which cells produce them. The central question: are IL-1β and PDGF synthesized locally at the cement-bone interface, and by which cell types?
Every time you revise a failed THA for aseptic loosening, you encounter the interface membrane. Before Jiranek et al., its histology had been described many times, but no one knew which cells were actually driving bone resorption or whether the cytokines involved were made locally or arrived from elsewhere.
This paper proved that IL-1β is synthesized on-site by macrophages and that fibroblasts are activated secondarily by this cytokine signal — not by phagocytosing particles themselves. That distinction matters: it means blocking the cytokine signal (rather than just reducing particle load) is a valid therapeutic target.
When you see aggressive osteolysis on a revised hip, think macrophage-IL-1β-fibroblast-PDGF cascade. The interface membrane is not just scar tissue. It is an active inflammatory organ producing bone-resorbing cytokines in a self-amplifying loop.
This work was the molecular foundation that launched a decade of osteolysis research, directly enabling Goodman et al.'s 1998 cellular profiling of revised hip and knee tissue and Ramage et al.'s 2007 identification of RANKL in osteolytic membranes. Both of which built on the macrophage-fibroblast-cytokine framework established here.
This 1993 retrieval study analyzed interface membrane tissue from 10 failed cemented polyethylene acetabular components. Using in situ hybridization and immunohistochemistry together — for the first time in human arthroplasty tissue — it identified which cytokines are produced in vivo and which cells produce them. The central question: are IL-1β and PDGF synthesized locally at the cement-bone interface, and by which cell types?
Every time you revise a failed THA for aseptic loosening, you encounter the interface membrane. Before Jiranek et al., its histology had been described many times, but no one knew which cells were actually driving bone resorption or whether the cytokines involved were made locally or arrived from elsewhere.
This paper proved that IL-1β is synthesized on-site by macrophages and that fibroblasts are activated secondarily by this cytokine signal — not by phagocytosing particles themselves. That distinction matters: it means blocking the cytokine signal (rather than just reducing particle load) is a valid therapeutic target.
When you see aggressive osteolysis on a revised hip, think macrophage-IL-1β-fibroblast-PDGF cascade. The interface membrane is not just scar tissue. It is an active inflammatory organ producing bone-resorbing cytokines in a self-amplifying loop.
This work was the molecular foundation that launched a decade of osteolysis research, directly enabling Goodman et al.'s 1998 cellular profiling of revised hip and knee tissue and Ramage et al.'s 2007 identification of RANKL in osteolytic membranes. Both of which built on the macrophage-fibroblast-cytokine framework established here.